Abstract 1732P
Background
Systemic therapy availability in Ukraine is fluid due to the war. This information is key to optimizing cancer care.
Methods
Online surveys assessing cancer treatment capacity were distributed to physicians in Ukraine through cancer-focused social media in April 2023. Results were analyzed with descriptive statistics and Fisher’s exact test.
Results
15 oncologists from 14 oncology centers and 12 hematologists from 9 hematology centers completed surveys, including 3 (25%) and 4 (27%), respectively, from the more war-affected Northern, Southern, and Eastern Ukraine. Of the 36 drugs used for solid tumors, limited availability (half of the time, rarely available, or unavailable) was reported for 11 (31%) drugs by 2-4 (14-29%) respondents: cisplatin, cyclophosphamide, doxorubicin, etoposide, fluorouracil, ifosfamide, methotrexate, vincristine, filgrastim, dexamethasone, tamoxifen. 7 (19%) had limited availability per 5-6 (36-42%): capecitabine, irinotecan, mesna, anastrozole, leuprolide, zoledronic acid, erlotinib. 12 (33%) drugs were limited per 7-8 (50-57%): abiraterone, bleomycin, carboplatin, docetaxel, gemcitabine, oxaliplatin, paclitaxel, vinblastine, vinorelbine, folinic acid, bicalutamide, trastuzumab. 7 (19%) were limited per 8-13 (57%-93%): nivolumab, diethylstilbestrol, bevacizumab, palbociclib, trastuzumab emtansine, sorafenib. Of 31 drugs used for hematologic malignancies, 4 (21%) were limited in availability per 2-4 respondents: vincristine, bortezomib, imatinib, azacitidine. 5 (16%) were limited per 5-6: bendamustine, filgrastim, doxorubicin, lenalidomide, hydroxycarbamide. 10 (32%) were reported to be limited by 7-8: rituximab, thalidomide, vinblastine, chlorambucil, bleomycin, methotrexate, daunorubicin, nilotinib. 10 (32%) were limited per 9-12: ibrutinib, mercaptopurine, eltrombopag, erythropoietin, thrombopoietin, ruxolitinib, venetoclax, brentuximab, gemtuzumab, obinutuzumab. Drug availability did not differ by country region (p > 0.05).
Conclusions
Shortages of essential anticancer drugs are a continued challenge in Ukraine during the war. Results are limited by small sample size and limited sampling from regions affected by active hostilities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1747P - The need for a better discussion between doctors and patients with regards to fertility preservation and vaginal rehab after anti cervical cancer treatments
Presenter: Bar Levy
Session: Poster session 23
1748P - Tackling childhood obesity epidemic on southern Europe through soft drink advertisement policies: Should oncology societies have a say?
Presenter: Konstantinos Kamposioras
Session: Poster session 23
1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)
Presenter: Beatrice Fervers
Session: Poster session 23
1751P - Re-ranking cancer mortality using years of life lost
Presenter: Cecilia Radkiewicz
Session: Poster session 23
1752P - Clinical benefit of immunotherapies in advanced cancer in France: A population-based estimate from 2014 to 2021
Presenter: Isabelle Borget
Session: Poster session 23
1753P - Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Presenter: Claudia Cardone
Session: Poster session 23
1754P - Towards a next-generation sequencing/comprehensive genomic profiling value framework: Systematic review for identifying new domains and adapting a diagnostic test value framework in Europe
Presenter: Federico Augustovski
Session: Poster session 23
1755P - Carbohydrate quality index and incidence of obesity-related cancers: The Seguimiento Universidad de Navarra (SUN) project
Presenter: Maria Olmedo López-frías
Session: Poster session 23
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23